Clinical Trial Update: Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating NTRA-2112 for intestinal malabsorption in preterm infants was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intestinal Malabsorption
• Prematurity

Drugs mentioned

• NTRA-2112

Snippet

Sponsor: Elgan Pharma Ltd. | Conditions: Premature Birth of Newborn, Intestinal Malabsorption | Phase 3 | Status: TERMINATED | Results posted: 2025-06-06